#AASLD2024 Archives - Page 2 of 3

AASLD Featured New Voices | Terry Yip and Jimmy Lai Explore the New Progress of Liver Disease

By Mourabit Halima 2024.12.05

Editor's note: At the recent AASLD 2024, the annual meeting of the American Association for the Study of Liver Diseases, top experts from the global liver disease field gathered to…

AASLD 2024丨Weight-Loss Surgery vs. Medication: A 5-Year Mortality Comparison in MAFLD Patients

By Peng Longmei 2024.12.04

The rising mortality rate among patients with metabolic dysfunction-associated fatty liver disease (MAFLD) underscores the need for effective interventions. At the 2024 AASLD Annual Meeting, Dr. Leith Ghani from the…

AASLD 2024丨Dr. Qing Xie’s Team: TMF Improves Efficacy and Safety in ALT-Normal Chronic HBV Patients—Midterm Results from the PROMOTE Study

By Mourabit Halima 2024.12.04

At the 2024 AASLD Annual Meeting, Dr. Qing Xie's team from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, presented findings on the efficacy and safety of a novel…

Dr.Hong You and Dr.Wei Chen’s Team Proliferative T Cell Subpopulations in the Liver Promote Fibrosis Reversal in CHB Patients After Antiviral Therapy

By Qingyuan Liu 2024.12.03

Chronic Hepatitis B (CHB) is a prevalent chronic inflammatory liver disease in China, often resulting in sustained hepatic parenchymal damage, liver fibrosis, and adverse outcomes such as cirrhosis, liver failure,…

AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure

By El Bachir MOURABIT 2024.12.03

From November 15-19, 2024, the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) was held in San Diego, USA. At this prestigious event, Dr.…

AASLD 2024 | Nadege Pelletier: Exploring new hope for innovative immunotherapy for chronic hepatitis B

By Mourabit Halima 2024.12.03

Editor's note: Chronic hepatitis B (CHB) is a major public health problem worldwide. Although traditional antiviral drugs can inhibit viral replication to some extent, they are still inadequate in achieving…

AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations

By Lisa Cui 2024.12.02

The 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) took place in San Diego, USA, from November 15 to 19, 2024. Six research projects…

AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations

By El Bachir MOURABIT 2024.12.02

Hepatocellular carcinoma (HCC) imposes a significant health and economic burden on patients. Screening, recognized as an effective strategy to improve early diagnosis rates in high-risk populations, has garnered broad acknowledgment…

AASLD 2024丨Dr. Qing Xie ‘s Team: Digital Precision Screening and Risk Stratification Improve Early Detection of Liver Cancer in China

By Mourabit Halima 2024.11.29

Liver cancer poses a significant public health challenge in China, with approximately 367,700 new cases in 2022, accounting for 42.5% of global incidence. However, the five-year survival rate is a…

Chinese Contributions at AASLD 2024: Dr. Yanyan Yu and Dr. Jinghang Xu’s Team Reveal Clinical Features and Prognostic Factors of HBV-Associated Glomer

By El Bachir MOURABIT 2024.11.26

At the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, two significant studies by Dr. Yanyan Yu and Dr. Jinghang Xu from Peking University First Hospital…